U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder Dec 10, 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder Nov 14, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview Nov 7, 2019
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease Oct 28, 2019
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder Oct 8, 2019
VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder Aug 15, 2019
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray Jul 23, 2019
VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview Jun 25, 2019
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine Jun 20, 2019
